Such interventions may need to extend beyond addressing well-described patient and practitioner behaviors to target policy-based solutions that reduce high medication costs, including for GLP1-RA and SGLT2i therapies.33,34 Elimination or substantial lowering of out-of-pocket costs has been demonstrated in adjacent disciplines of cardiovascular diseases to be associated with improved medication adherence, while not influencing overall health system costs.35 Here, GLP1R is linked to cardiovascular disorder.